Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced CancerRoy S. Herbst, David S. Mendelson, Razelle Kurzrock et al.|Journal of Clinical Oncology|2010Cited by 443